About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Clinicaltrials.gov identifier NCT03933813

Recruitment Status Recruiting

First Posted May 1, 2019

Last update posted June 18, 2020

Study Description

Brief summary:

This study tests the hypothesis that IV iron sucrose infusions given to iron deficient ovarian cancer patients prior to debulking surgery can improve pre-operative iron stores and decrease transfusion of packed red blood cells in the peri-operative period. 21 participants at least 18 years of age with epithelial ovarian cancer of any stage requiring neoadjuvant chemotherapy and surgery will be enrolled. Participants will be on study for a period of up to 3 months.

  • Condition or Disease:Epithelial Ovarian Cancer
    Anemia
    Iron Deficiency Anemia
  • Intervention/Treatment: Other: Iron Sucrose
  • Phase: Phase 1/Phase 2
Detailed Description

Iron deficiency and anemia are common in cancer patients. Data from the University of Wisconsin (UW) suggest that more than 50% of ovarian cancer patients undergo blood transfusion during their cancer treatments. Transfusion rates are particularly high in patients who receive neoadjuvant chemotherapy (NACT), despite multiple opportunities to diagnose and treat anemia prior to surgery. Blood transfusions have been associated with worse survival in ovarian cancer patients. Seventy-seven percent of ovarian cancer patients who receive NACT at the UW are anemic prior to surgery, and the same percentage receive a perioperative blood transfusion, defined as a blood transfusion within 72 hours of surgery. Iron deficiency without anemia is also common in cancer patients, though little has been published regarding how frequently it occurs in ovarian cancer patients. Functional iron deficiency, a lack of iron incorporation into erythroid precursors despite adequate iron stores, is also common in cancer patients. Study investigators hypothesize that IV iron sucrose infusions given to iron deficient ovarian cancer patients prior to debulking surgery can improve pre-operative iron stores and decrease transfusion of packed red blood cells in the peri-operative period. Eligible participants will have a new epithelial ovarian cancer diagnosis, with planned neoadjuvant chemotherapy and interval debulking surgery. The study cohort will consist of participants with iron deficiency without anemia (defined below) prior to starting chemotherapy. Iron deficient participants with anemia are already offered iron sucrose infusions as part of their standard of care treatment. The study group will include participants with planned neoadjuvant chemotherapy and debulking surgery with a normal Hgb within 30 days of study enrollment. Iron studies including ferritin, transferrin, total iron binding capacity (TIBC), reticulocyte count and serum iron, will be performed on these participants for research purposes only. Consent will be obtained prior to drawing research-related iron studies. The majority of participants will have Hgb levels available in their records from the last 30 days, either from the UW, or from a referring institution. If this is not the case, pre-chemotherapy lab studies will be obtained the day of their visit, which would routinely include a Hgb level. Participants will sign a consent to receive four IV iron sucrose transfusions, prior to their debulking surgery, and be followed for prospective data collection. Consent will be signed for the infusion and for prospective data collection related to future laboratory studies and rates of transfusion of blood products. Participants with a normal Hgb and normal iron studies will participate in the prospective data collection portion of this study only. Prospective data collection will continue until subjects have completed first-line chemotherapy. Subjects will be enrolled until 21 evaluable participants have been enrolled. Evaluable participants will have true or functional iron deficiency without anemia and have received at least one IV iron sucrose infusion. Iron studies will be repeated 21 days (+/- 7 days) after last infusion in participants who receive IV iron sucrose. Participants with persistent iron deficiency will be referred to hematology.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 40 participants
  • Intervention Model: Single Group Assignment
  • Intervention Model Description: Unblinded, window of opportunity trial
  • Masking: None (Open Label) ()
  • Primary Purpose: Supportive Care
  • Official Title: Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: January 2021
  • Estimated Study Completion Date: January 2021
Arms and interventions
Arm Intervention/treatment
Experimental: IV Iron Sucrose
Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period
Other: Iron Sucrose
Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
Outcome Measures
  • Primary Outcome Measures: 1. Rate of Peri-operative Blood Transfusion [ Time Frame: Within 72 hours of surgery, up to 5 weeks on study ]
    Defined as a transfusion of Packed Red Blood Cells (PRBCs) within 72 hours of surgery, in iron deficient ovarian cancer patients who receive IV iron sucrose therapy prior to surgery compared to a historical controls (historically 77%). The primary endpoint will be summarized with descriptive statistics and conducted using a Fisher's exact test and exact binomial confidence intervals. Point estimates and exact 95% confidence intervals (CI) will be calculated.
  • Secondary Outcome Measures: 1. Rate of Iron Deficiency Anemia [ Time Frame: up to 21 days following surgery ]
    The rate of iron deficiency anemia in all ovarian cancers patients at the University of Wisconsin. This endpoint will be summarized with descriptive statistics and conducted using a Fisher's exact test and exact binomial confidence intervals. In particular, point estimates and exact 95% confidence intervals (CI) will be calculated.
  • 2. Rate of Resolution of Iron Deficiency Anemia After Intervention [ Time Frame: up to 21 days following surgery ]
    Iron deficiency anemia is defined as ferritin > 30 ng/mL and iron saturation of < 50%. This endpoint will be summarized with descriptive statistics and conducted using a Fisher's exact test and exact binomial confidence intervals. In particular, point estimates and exact 95% confidence intervals (CI) will be calculated.
  • 3. Incidence of Treatment Emergent Adverse Events (AEs) [ Time Frame: up to 21 days following surgery ]
    Safety and Tolerability will be monitored by measuring adverse events data with date of onset (or worsening) on or after the start-date treatment with iron sucrose and end of study (post-operative visit (7 to 21 days following surgery). AEs are defined as mild, moderate and severe. This endpoint will be summarized with descriptive statistics and conducted using a Fisher's exact test and exact binomial confidence intervals. In particular, point estimates and exact 95% confidence intervals (CI) will be calculated.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Provide written informed consent.

- Has a diagnosis of true or functional iron deficiency without anemia within 30 days of
treatment on this protocol

- Iron deficiency without anemia (normal Hgb >/= 11.6 g/dL but ferritin 30 ng/ml and iron saturation
of age 50 with no menses for at least 1 year)

- Participants of reproductive potential must agree to use effective birth control
during study participation. Effective birth control is defined as any FDA approved
contraceptive method

Exclusion Criteria:

- Currently taken any form of oral or intravenous iron therapy. Patients must have
discontinued iron therapy > 30 days from study entry

- Current untreated or unstable heart disease

- History of iron induced hypersensitivity or allergy

- History of leukemia, lymphoma, or other myelodysplastic disorders

- Prior diagnosis of hemochromatosis or hemoglobinopathy (e.g. thalassemia)

- Any subject with immediate requirement for radiotherapy

- Concomitant enrollment in another clinical trial interfering with endpoints on this
study

- Any medical condition which could compromise participation in the study according to
the investigator's assessment

- Female patient who is pregnant or breast-feeding

- Patients unwilling or unable to comply with the protocol or unable to give informed
consent

Contacts and Locations
Contacts

Contact: Cancer Connect 800-622-8922 clinicaltrials@cancer.wisc.edu

Locations

United States, Wisconsin
University of Wisconsin Carbone Cancer Center
Madison

Sponsors and Collaborators

University of Wisconsin, Madison

Investigators

Principal Investigator: Lisa Barroilhet, MD University of Wisconsin, Madison

More Information
  • Responsible Party: University of Wisconsin, Madison
  • ClinicalTrials.gov Identifier: NCT03933813 History of Changes
  • Other Study ID Numbers: UW18106, 2019-0022, A532820, SMPH/OB-GYN/GYN ONCOLOGY, NCI-2019-02185, Protocol Version 8/15/2019
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: June 18, 2020
  • Last Verified: June 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by University of Wisconsin, Madison: ovarian cancer
    anemia
    iron deficiency
    blood transfusion
  • Additional relevant MeSH terms: Anemia, Iron-Deficiency
    Ovarian Neoplasms
    Carcinoma, Ovarian Epithelial
    Anemia